A Survey of Melatonin in Dietary Supplement Products Sold in the United States
- PMID: 39482109
- DOI: 10.1002/dta.3823
A Survey of Melatonin in Dietary Supplement Products Sold in the United States
Abstract
In the United States, melatonin products are widely available as dietary supplements. During the past few decades, melatonin products have gained popularity primarily as a sleep aid, with a variety of product forms available for different age groups of consumers. Recent reports have highlighted a rise in melatonin ingestion among children reported to poison control centers. The increased use of melatonin-containing products, the diversity in product forms, and reported label discrepancies has emphasized the need for additional research to better understand the marketplace. This work aims to measure melatonin content in products sold as dietary supplements and marketed for children, evaluate method performance across different product categories, and determine if product form has an impact on melatonin stability. One hundred ten (110) dietary supplement products labeled to contain melatonin and marketed towards children were purchased and analyzed using a targeted LC-MS/MS method validated for the qualitative determination of serotonin and quantification of melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), and N1-acetyl-5-methoxykynuramine (AMK). Melatonin was identified in 108 of 110 products (98%) with a median concentration of 1.2 mg/g (range: 0.017-130 mg/g) or 1.7 mg/serving (range: 0.042-50 mg/serving). Further, in the tested products, melatonin content ranged from 0% to 667% of the label declaration. This study provides evidence to inform safety assessments and investigate potential factors that may influence reported concentrations, such as product stability and matrix influences.
Keywords: LC‐MS/MS; dietary supplements; melatonin.
Published 2024. This article is a U.S. Government work and is in the public domain in the USA.
References
-
- B. Salehi, F. Sharopov, P. V. T. Fokou, et al., “Melatonin in Medicinal and Food Plants: Occurrence, Bioavailability, and Health Potential for Humans,” Cells 8, no. 7 (2019): 681.
-
- J. Liira, J. H. Verbeek, G. Costa, et al., “Pharmacological Interventions for Sleepiness and Sleep Disturbances Caused by Shift Work,” Cochrane Database of Systematic Reviews 2014, no. 8 (2014): CD009776.
-
- A. Herxheimer and K. J. Petrie, “Melatonin for the Prevention and Treatment of Jet Lag,” Cochrane Database of Systematic Reviews 2010, no. 2 (2002): CD001520.
-
- H. Edemann‐Callesen, H. K. Andersen, A. Ussing, et al., “Use of Melatonin for Children and Adolescents With Chronic Insomnia Attributable to Disorders Beyond Indication: A Systematic Review, Meta‐Analysis and Clinical Recommendation,” EClinicalMedicine 61 (2023): 102049.
-
- NAS/IOM. Institute of Medicine (US) and National Research Council (US), “Committee on the Framework for Evaluating the Safety of Dietary Supplements. Appendix F Melatonin: Prototype Monograph Summary,” in Dietary Supplements: A Framework for Evaluating Safety, (Washington (DC): National Academies Press, 2005).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
